Remitting seronegative symmetrical synovitis with pitting edema
(Redirected from RS3PE)
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (often abbreviated as RS3PE) is a rare clinical syndrome characterized by the onset of acute inflammation in the joints (synovitis) and swelling (edema) in the extremities. The condition is typically seronegative, meaning that it does not show the presence of certain antibodies often associated with rheumatic diseases.
Symptoms[edit | edit source]
The primary symptoms of RS3PE include sudden onset of pain and swelling in the joints, particularly in the hands and feet. The swelling often results in a condition known as pitting edema, where pressure applied to the skin leaves a dent that takes some time to fill back in. Other symptoms may include stiffness in the affected joints, fatigue, and in some cases, mild fever.
Causes[edit | edit source]
The exact cause of RS3PE is unknown. However, it is believed to be associated with various underlying conditions such as cancer, infections, and autoimmune diseases. Some studies suggest that it may be triggered by an overactive immune response.
Diagnosis[edit | edit source]
Diagnosis of RS3PE is primarily based on clinical examination and the patient's medical history. Laboratory tests may be conducted to rule out other conditions. Imaging tests such as ultrasound and magnetic resonance imaging (MRI) may also be used to assess the extent of inflammation and edema.
Treatment[edit | edit source]
Treatment for RS3PE typically involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain. In severe cases, corticosteroids may be prescribed. Physical therapy may also be recommended to improve joint function.
Prognosis[edit | edit source]
The prognosis for RS3PE is generally good, with most patients experiencing remission within a few months of treatment. However, the condition can recur in some cases.
See also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD